140.49
-5.50 (-3.77%)
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (US) | Mixed | Bearish |
Medical Devices (Global) | Mixed | Bearish | |
Stock | TransMedics Group, Inc. | Bullish | Bullish |
Stockmoo Score
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
Sector | Healthcare |
Industry | Medical Devices |
Investment Style | Small Growth |
Ownership
Name | Date | Shares Held |
---|---|---|
Sandhill Capital Partners Llc | 31 Mar 2024 | 733,671 |
52 Weeks Range | ||
Price Target Range | ||
High | 208.00 (Needham, 48.05%) | Buy |
Median | 179.00 (27.41%) | |
Low | 145.00 (Morgan Stanley, 3.21%) | Hold |
Average | 180.00 (28.12%) | |
Total | 5 Buy, 1 Hold | |
Avg. Price @ Call | 154.11 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Needham | 23 Aug 2024 | 208.00 (48.05%) | Buy | 175.66 |
21 Aug 2024 | 208.00 (48.05%) | Buy | 172.95 | |
Stephens & Co. | 02 Aug 2024 | 178.00 (26.70%) | Buy | 150.10 |
Canaccord Genuity | 01 Aug 2024 | 169.00 (20.29%) | Buy | 151.51 |
Oppenheimer | 01 Aug 2024 | 200.00 (42.36%) | Buy | 151.51 |
Piper Sandler | 01 Aug 2024 | 180.00 (28.12%) | Buy | 151.51 |
15 Jul 2024 | 170.00 (21.01%) | Buy | 144.35 | |
Morgan Stanley | 15 Jul 2024 | 145.00 (3.21%) | Hold | 144.35 |
Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
---|---|---|---|---|
KHAYAL TAMER I | - | 159.38 | -2,960 | -471,765 |
Aggregate Net Quantity | -2,960 | |||
Aggregate Net Value ($) | -471,765 | |||
Aggregate Avg. Buy ($) | - | |||
Aggregate Avg. Sell ($) | 159.38 |
Name | Holder | Date | Type | Quantity | Price | Value ($) |
---|---|---|---|---|---|---|
KHAYAL TAMER I | Officer | 03 Sep 2024 | Automatic sell (-) | 2,960 | 159.38 | 471,765 |
KHAYAL TAMER I | Officer | 03 Sep 2024 | Option execute | 2,960 | - | - |
Date | Type | Details |
---|---|---|
21 Aug 2024 | Announcement | TransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference |
20 Aug 2024 | Announcement | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
31 Jul 2024 | Announcement | TransMedics Reports Second Quarter 2024 Financial Results |
29 Jul 2024 | Announcement | TransMedics to Present at the Canaccord Genuity 44th Annual Growth Conference |
18 Jul 2024 | Announcement | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
17 Jul 2024 | Announcement | TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024 |
21 Jun 2024 | Announcement | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |